AcquisitionOther
HEAT BIOLOGICS, INC. acquired Elusys Therapeutics,
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
HEAT BIOLOGICS, INC. -> Elusys Therapeutics, · $350 million
The strategic acquisition of Elusys is intended to enhance Heat's immunotherapy portfolio and further position Heat to take a lead role in the biodefense space.
Open source record (SEC) ↗